Dr Michael Lean (Chair of Human Nutrition [Medicine], University of Glasgow, Glasgow, UK) reviews the Diabetes Remission Clinical Trial (DiRECT). Weight loss is the most important thing patients can do to reduce glycated hemoglobin, reduce/eliminate comorbidities, and eventually gain diabetes remission. The DiRECT trial, funded by Diabetes UK, has been set up to help patients lose weight without bariatric surgery, and in turn become non-diabetic. Post-hoc analyses of the DiRECT trial have shown that almost 50% of patients can achieve remission of diabetes through weight loss, but the question remains, how do we identify these patients? Results showed there was no difference in males and females, older patients performed better than their younger counterparts, and certain medications hindered weight loss. Finally, Dr Lean highlights one of the main focuses of ADA 2018, which is drivers of disease progression, being high lipids and high insulin – both of which are caused by weight gain.
1. What was the background and rationale behind the Diabetes Remission Clinical Trial (DiRECT)? (0:14)
2. What were the findings of the post-hoc analysis presented at this meeting? (1:35)
3. What are the next steps in this area of research over the coming years? (3:08)
4. What are you highlights from this year’s ADA meeting? (4:15)
Filmed at the American Diabetes Association (ADA) Annual Meeting, June 2018
Related Videos In Diabetes
Dr Teresa Quattrin, EASD 2020 – Updates from the T1GER study
We spoke with Teresa Quattrin (University at Buffalo, Oishei Children’s Hospital) following her presentation of the T1GER study, which investigated the effect of treatment with golimumab in children, adolescents, and young adults with newly diagnosed type 1 diabetes. Disclosures: Tersea Quattrin discloses the following: Consultant to Janssen Research & Development Clinical Trial, Principal Investigator at […]
Prof. Hiddo Lambers Heerspink, EASD 2020 – Updates from the DAPA-CKD trial
touchENDOCRINOLOGY were delighted to speak with Prof. Hiddo Lambers Heerspink to hear more about the highly anticipated results of DAPA-CKD, investigating dapagliflozin in patients with chronic kidney disease with or without type 2 diabetes. Disclosures: Prof. Lambers Heerspink discloses the following: Grant Funding and Consultancy from AstraZeneca, Boehringer Ingelheim and AbbVie, Steering committee member for […]
Dr Ramzi Ajjan, EASD 2020 – Updates from the LIBERATES trial
We spoke with Dr Ramzi Ajjan (University of Leeds and Leeds Teaching Hospitals Trust) at Virtual EASD 2020 following the presentation of the results from the LIBERATES trial (improving gLucose control in patIents with diaBEtes following myocaRdial infArction: The role of a novEl glycaemic monitoring). Disclosures: Ramzi Ajjan has received institutional research grants from Abbott, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!